Platelet Rich Plasma (PRP) as Terapeutical Option in Erectil Disfunction (DE)
Status:
ENROLLING_BY_INVITATION
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
Patients are randomized into 2 groups (A and B), subsequently group A is subjected to a cycle of 6 weekly injections of 3 ml of autologous PRP while group B is subjected to 6 weekly injections of 1 ml of caverject (alprostadil) 20 mcg. After 4 (four) weeks the groups will be crossed, so group A will be subjected to 6 weekly injections of 1 ml of caverject (alprostadil) 20 mcg while group B will be subjected to a cycle of 6 weekly injections of 3 ml of autologous PRP.
Phase:
NA
Details
Lead Sponsor:
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari